Citadel Advisors’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Citadel Advisors’s Portfolio RCKTW Stock Details RCKTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92K	Buy	310,370 +373	+0.1%	+$4	﹤0.01%	13553
2026 Q1	$6.51K	Sell	309,997 -1,492	-0.5%	-$30	﹤0.01%	12799
2025 Q4	$6.17K	Sell	311,489 -1,300	-0.4%	-$42	﹤0.01%	12458
2025 Q3	$11.3K	Sell	312,789 -2,053	-0.7%	-$80	﹤0.01%	12556
2025 Q2	$9.07K	Sell	314,842 -2,461	-0.8%	-$102	﹤0.01%	12202
2025 Q1	$14.9K	Sell	317,303 -20,301	-6%	-$1.32K	﹤0.01%	13342
2024 Q4	$11.6K	Sell	337,604 -5,793	-2%	-$283	﹤0.01%	13544
2024 Q3	$24K	Sell	343,397 -27,202	-7%	-$2.1K	﹤0.01%	12632
2024 Q2	$22.3K	Buy	370,599 +5,776	+2%	+$657	﹤0.01%	12541
2024 Q1	$109K	Buy	364,823 +64,523	+21%	+$20.4K	﹤0.01%	11232
2023 Q4	$147K	Sell	300,300 -24,549	-8%	-$6.82K	﹤0.01%	10418
2023 Q3	$49.6K	Sell	324,849 -27,965	-8%	-$4.41K	﹤0.01%	11768
2023 Q2	$65.4K	Sell	352,814 -4,636	-1%	-$849	﹤0.01%	11486
2023 Q1	$58.4K	Buy	+357,450	New	+$69K	﹤0.01%	11954

Other funds holding RCKTW

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Citadel Advisors's RCKTW Position: Q2 2026 in Review

Citadel Advisors increased its Rocket Pharmaceuticals Warrant (RCKTW) stake by 0.12% in Q2 2026, buying an estimated $4 and bringing the position to 310,370 shares worth $1.92K. The position accounts for ﹤0.01% of the portfolio, ranked #13553.

Citadel Advisors first reported a position in RCKTW in Q1 2023 and has held it in 14 quarters since. The position peaked at $147K in Q4 2023. 11 funds tracked by Wall St. Rank hold RCKTW as of Q2 2026.

Citadel Advisors held 310,370 shares of Rocket Pharmaceuticals Warrant worth $1.92K as of Q2 2026.
Citadel Advisors bought 373 Rocket Pharmaceuticals Warrant shares in Q2 2026, an estimated $4.
Rocket Pharmaceuticals Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13553 holding.
Citadel Advisors first reported a position in Rocket Pharmaceuticals Warrant in Q1 2023 and has held it in 14 quarters since.
Citadel Advisors's Rocket Pharmaceuticals Warrant position peaked at $147K in Q4 2023.
11 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.